AnalystsInsight

Rami Katkhuda (LifeSci Capital): Analyst Track Record and Price‑Target Accuracy

How often Rami Katkhuda’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 605 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

What changed since Oct 12

Exent re-checks this page every day. Ratings appear 30 days after they are published; live calls are in Gems.

+1 new rating (VERA)

Key takeaways

  • Rami Katkhuda ranks #414 of 1,000 analysts in Exent’s scoring (4.8★).
  • 24.7% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 131 days; 51.9% of calls were up 12 months later.
  • Most‑covered stocks: IRON, VRDN, MLTX, DNTH.
  • Free on Exent: Rami Katkhuda’s full record, with ratings 3 days after publication.

Rami Katkhuda’s track record at a glance

Rami Katkhuda of LifeSci Capital ranks #414 of the 1,000 analysts Exent scores, with a 4.8★ rating and a focus on healthcare. Over a 7‑year lookback, 24.7% of Rami’s price targets were reached, 27.7 points below the 52.4% average across all analysts.

MetricRami KatkhudaAll analysts
Price‑target hit rate24.7%52.4%
Median days to hit target131 days91 days
Calls up after 12 months51.9%64.0%
Median 12‑month return of calls+4.8%+13.4%
Hit rate, last 2 years24.7%—
Average worst drop after a call−31.5%—
Ratings in the sample605—
Stocks covered13—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetRami Katkhuda
Under 30 days8.1%
30–90 days27.0%
90–180 days32.4%
Over 180 days32.4%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Rami Katkhuda covers most

StockRatings in the sample
IRON50
VRDN46
MLTX44
DNTH44
AMLX41
ELDN39
VERA38
MLYS32

In the past year Rami’s ratings were 100% Buy, 0% Hold and 0% Sell.

Rami Katkhuda’s latest ratings

DateStockActionRatingPrice target
Sep 15, 2026VERAReiterated: BuyBuy$90.00
Sep 10, 2026IRONReiterated: BuyBuy$100.00
Sep 9, 2026ABSIInitiated Coverage: BuyBuy$16.00
Sep 3, 2026ELDNReiterated: BuyBuy$8.00
Sep 3, 2026JBIOReiterated: BuyBuy$42.00
Aug 27, 2026IRONReiterated: BuyBuy$100.00
Aug 22, 2026AMLXReiterated: BuyBuy$44.00
Aug 18, 2026AMLXRated: BuyBuy$44.00
Aug 14, 2026ELDNReiterated: BuyBuy$8.00
Aug 13, 2026YARWReiterated: BuyBuy$56.00
Aug 12, 2026MLYSReiterated: BuyBuy$54.00
Aug 12, 2026ELOXReiterated: BuyBuy$40.00
  • Sep 15, 2026
    Stock
    VERA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $90.00
  • Sep 10, 2026
    Stock
    IRON
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $100.00
  • Sep 9, 2026
    Stock
    ABSI
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $16.00
  • Sep 3, 2026
    Stock
    ELDN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $8.00
  • Sep 3, 2026
    Stock
    JBIO
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $42.00
  • Aug 27, 2026
    Stock
    IRON
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $100.00
  • Aug 22, 2026
    Stock
    AMLX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $44.00
  • Aug 18, 2026
    Stock
    AMLX
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $44.00
  • Aug 14, 2026
    Stock
    ELDN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $8.00
  • Aug 13, 2026
    Stock
    YARW
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $56.00
  • Aug 12, 2026
    Stock
    MLYS
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $54.00
  • Aug 12, 2026
    Stock
    ELOX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $40.00

Rami’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Rami Katkhuda’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Rami Katkhuda ranks #414 of 1,000 with a 4.8★ rating. 24.7% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 51.9% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Rami Katkhuda’s success rate is 50.0% by the ranking source and 24.7% by Exent’s price-target hit-rate backtest, with a median of 131 days to reach a target.

Rami Katkhuda (LifeSci Capital) covers 13 stocks, mostly in healthcare. The most frequently rated are IRON, VRDN, MLTX, DNTH, AMLX.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.